leuprolide and Chronic-Disease
leuprolide has been researched along with Chronic-Disease* in 12 studies
Reviews
1 review(s) available for leuprolide and Chronic-Disease
Article | Year |
---|---|
Primary gonadotropin-releasing hormone agonist therapy for suspected endometriosis: a nonsurgical approach to the diagnosis and treatment of chronic pelvic pain.
Chronic pelvic pain is a condition that affects one in seven women of reproductive age in the United States. Direct and indirect medical costs associated with this condition are estimated to be more than $3 billion annually before factoring in the costs of diagnostic testing. At many medical centers, endometriosis is the most common single cause of chronic pelvic pain; other causes include intra-abdominal adhesions, chronic pelvic inflammatory disease, ovarian cysts, and adenomyosis. The current approach to diagnosis and treatment of chronic pelvic pain is a two-step approach, with medical history, physical examination, laboratory testing, and empiric therapy (nonsteroidal anti-inflammatory drugs, oral contraceptives, and/or antibiotics) comprising Step 1 and surgical diagnosis with laparoscopy as Step 2. At many centers, the most common diagnosis at the time of laparoscopy for chronic pelvic pain is endometriosis, typically minimal to mild disease that can be effectively treated with hormonal therapy. Therefore, a rational alternative approach is a 3-month empiric course of therapy with a gonadotropin-releasing hormone agonist before laparoscopy. The advantages of this approach are the high rate of pain relief in women, the possibility of avoiding an invasive procedure (laparoscopy), the ability to extend therapy, if pain is relieved, to the full 6-month therapeutic course of endometriosis, and a potentially lower cost relative to laparoscopy. Topics: Chronic Disease; Cost of Illness; Endometriosis; Female; Hormone Antagonists; Humans; Laparoscopy; Leuprolide; Managed Care Programs; Pelvic Pain; United States | 1997 |
Trials
3 trial(s) available for leuprolide and Chronic-Disease
Article | Year |
---|---|
Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain.
This pilot study examined the effect of a low-dose E and pulsed progestogen hormone therapy (HT) regimen for add-back during long-term GnRH-agonist therapy on bone mineral density (BMD) in five patients with stage IV endometriosis. Bone mineral density was stable after initiation of HT for the entire follow-up period (up to 10 years). One patient stopped her treatment on two occasions to conceive and was successful each time with delivery of a normal baby. No patient had return of pelvic pain after HT add-back. Topics: Adult; Bone Demineralization, Pathologic; Bone Density; Chronic Disease; Drug Combinations; Endometriosis; Estradiol; Female; Fertility Agents, Female; Hormone Replacement Therapy; Humans; Leuprolide; Pelvic Pain; Pilot Projects; Progestins; Treatment Outcome | 2006 |
Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group.
To evaluate and compare the safety and efficacy of leuprolide versus placebo in managing chronic pelvic pain in women with clinically suspected endometriosis.. Women 18-45 years of age with moderate to severe pelvic pain of at least 6 months' duration underwent extensive, noninvasive diagnostic testing and laboratory evaluation, including pelvic ultrasound, complete blood count, determination of erythrocyte sedimentation rate, and endocervical cultures. Those with clinically suspected endometriosis were randomized to double-blind treatment for 3 months with depot leuprolide (3.75 mg/mo) or placebo. The accuracy of the clinical diagnosis of endometriosis was evaluated by posttreatment laparoscopy.. Of 100 women randomized, 95 completed the study: 49 in the leuprolide group and 46 in the placebo group. Women in the leuprolide group had clinically and statistically significant (P < or = .001) mean improvements from baseline after 12 weeks of therapy in all pain measures. These mean improvements were significantly greater (P < or = .001) than those in the placebo group. At 12 weeks, mean decreases in physician-rated scores for dysmenorrhea, pelvic pain, and pelvic tenderness were 1.7, 1.0, and 0.8 points greater, respectively, in the leuprolide group than in the placebo group (on a four-point scale). Thirty-eight (78%) of 49 and 40 (87%) of 46 patients in the leuprolide and placebo groups, respectively, had laparoscopically confirmed endometriosis after 12 weeks of treatment. No women withdrew from the study because of adverse events.. Depot leuprolide was effective and safe for treating patients with chronic pelvic pain and clinically suspected endometriosis, confirming the potential of its empiric use in these patients. Topics: Adolescent; Adult; Algorithms; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Endometriosis; Female; Humans; Laparoscopy; Leuprolide; Middle Aged; Pelvic Pain | 1999 |
Hypothalamic modulation of nociception and reproduction in cluster headache. I. Therapeutic trials of leuprolide.
A slow-release gonadotropin-releasing hormone (Gn-RH) analogue was administered to 30 males suffering from chronic cluster headache (CH) in a placebo-controlled study with the aim of enhancing neurotransmission in the pain-suppressing systems of the hypothalamus through a feedback action involving neuroendocrine functions too. A significant improvement in the severity of the pain occurred together with the expected lowering of the libido and serum levels of testosterone and luteinizing hormone. We postulate that the benefit of the Gn-RH analogue relates to an impairment of neuronal modulation in cluster headache. Topics: Adult; Chronic Disease; Cluster Headache; Humans; Hypothalamus; Leuprolide; Luteinizing Hormone; Male; Middle Aged; Nociceptors; Receptors, Gonadotropin; Single-Blind Method; Testosterone | 1993 |
Other Studies
8 other study(ies) available for leuprolide and Chronic-Disease
Article | Year |
---|---|
Neurological improvement in patients with chronic spinal cord injury treated with leuprolide acetate, an agonist of GnRH.
It has been reported that gonadotropin‑releasing hormone (GnRH), and its analogue leuprolide acetate (LA), have neurotrophic properties; particularly in the regeneration of injured spinal cord in animal models and in the case of a patient with spinal cord injury (SCI). The aim of this study was to establish whether treatment with LA improves sensitivity, motor activity and independence in patients with chronic SCI. Patients were treated LA once a month for six months. They were evaluated at the beginning and at the end of treatment; using a sensitivity and motor impairment scale, according to the American Spinal Injury Association (ASIA), and grade of independence scale; employing the spinal cord independence measure (SCIM). Statistical analysis showed a significant improvement in the ASIA sensory score and the SCIM score when comparing the initial versus final evaluation after six months of LA administration. Some patients showed an increase in frequency of bowel movements. Treatment with LA induces improvements in sensitivity, motor activity and independence in patients with chronic SCI. One advantage of this protocol is that it is a non-invasive method of easy and safe application, with few side effects. Topics: Adolescent; Adult; Chronic Disease; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Recovery of Function; Spinal Cord Injuries; Treatment Outcome; Young Adult | 2018 |
Chronic vulvovaginal pruritus treated successfully with GnRH analogue.
A Medline search shows that this is the first reported case where vulvovaginal pruritus was treated successfully with a GnRH analogue. The report describes a patient with chronic premenstrual vulvovaginal pruritus thought to be attributable to autoimmune progesterone dermatitis. Topics: Adult; Antipruritics; Chronic Disease; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Menstruation Disturbances; Progesterone; Progestins; Pruritus; Pruritus Vulvae; Vaginal Diseases | 2006 |
The effect of a gonadotrophin-releasing hormone analogue as first-line management in cyclical pelvic pain.
One of the most common gynaecological causes of chronic pelvic pain is endometriosis. A lack of correlation between laparoscopic findings and pelvic pain has been reported. As endometriotic lesions are under hormonal influence, the effects of the gonadotrophin-releasing hormone (GnRH) analogues cause shrinkage of the deposits, reducing symptoms caused by them. We carried out a longitudinal, interventional pilot study, examining the effect of leuprorelin acetate 3.75 mg (Prostap SR, Wyeth) on pelvic pain prospectively. Preliminary data shows a decrease in pain scores from before to after treatment which is statistically significant (P<0.0001) as well as a general improvement in other symptoms. Laparoscopy showed that symptom intensity is not always related to severity of endometriosis and the worst symptoms may not necessarily be due to pathology. Therefore, it is beneficial to treat women with CPP with GnRH analogues as first-line management to relieve painful symptoms, avoid surgical risks and save money. Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometriosis; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Laparoscopy; Leuprolide; Longitudinal Studies; Pain Measurement; Patient Satisfaction; Pelvic Pain; Periodicity; Pilot Projects; Prospective Studies; Sampling Studies; Severity of Illness Index; Treatment Outcome | 2004 |
Hormonal manipulation in women with chronic, cyclic irritable bladder symptoms and pelvic pain.
Chronic, painful bladder symptoms are diagnostic and therapeutic challenges for urologists and gynecologists. The aims of this study were to evaluate women with menstrual cycle-related changes in their interstitial cystitis symptoms, to treat them with hormonal manipulation, and to follow them long term.. The cases of women who were referred to a tertiary care center with interstitial cystitis and menstrual cycle exacerbation of symptoms were evaluated in a retrospective study. Fifteen women had undergone laparoscopy that was followed immediately by cystoscopy and bladder hydrodistension. Patients were then treated with leuprolide acetate or oral contraceptive pills.. Patient age ranged from 23 to 48 years. The duration of symptoms ranged from 1 to 26 years. Ten patients (67%) had findings of both interstitial cystitis and peritoneal endometriosis. Five of 15 patients (33%) had interstitial cystitis, but no endometriosis was found. Symptoms improved for 8 of 9 women who were treated with leuprolide acetate and for 5 of 6 women who were treated with oral contraceptive pills. Patients were followed up for an average of 55 months.. Diagnostic laparoscopy should be considered together with hydrodistension of the bladder for women with pelvic pain and irritative bladder symptoms that are exacerbated premenstrually. Endometriosis is often present in patients with these complex symptoms. This is the first report of hormonal treatment for chronic, cyclic irritative bladder symptoms; improvement appears to occur even when endometriosis is not identified by laparoscopy. Topics: Adult; Chronic Disease; Contraceptives, Oral; Cystitis, Interstitial; Cystoscopy; Dilatation; Endometriosis; Female; Follow-Up Studies; Humans; Laparoscopy; Leuprolide; Menstrual Cycle; Middle Aged; Pelvic Pain; Peritoneal Diseases; Retrospective Studies; Treatment Outcome; Water | 2002 |
Evaluation of Lovelace Health Systems chronic pelvic pain protocol.
Although laparoscopy has been considered the gold standard for the diagnosis of endometriosis, it often fails to detect the disease and provide lasting pain relief. Motivated by concerns for patient well-being, treatment efficacy, and cost containment, Lovelace Health Systems of Albuquerque, New Mexico, turned to the Lovelace Chronic Pelvic Pain Protocol, based on a chronic pelvic pain algorithm used to identify potential candidates for therapy with gonadotropin-releasing hormone agonist (GnRH agonist). Since the protocol's introduction in January 1997, empiric therapy with GnRH agonist has proved beneficial to patients, physicians, and healthcare system budgets. Topics: Algorithms; Chronic Disease; Clinical Protocols; Decision Making; Endometriosis; Female; Gonadotropin-Releasing Hormone; Health Care Costs; Humans; Hysteroscopy; Leuprolide; New Mexico; Organizational Case Studies; Pelvic Pain; Program Evaluation | 1999 |
A gonadotropin-releasing hormone analog in chronic cluster headache [editorial].
Topics: Chronic Disease; Cluster Headache; Humans; Leuprolide | 1993 |
Chronic intestinal pseudoobstruction in a patient with heart-lung transplant. Therapeutic effect of leuprolide acetate.
After orthotopic heart-lung transplantation and immunosuppression, a patient developed intractable nausea and vomiting in association with chronic cytomegalovirus infection. Chronic intestinal pseudoobstruction was documented by antroduodenal manometric study. The patient was treated with leuprolide acetate with resolution of symptoms and improvement of intestinal motility abnormality. This case demonstrates an association of chronic viral infection with acquired intestinal motor disorders. Gastrointestinal complications that are common after organ transplantation might be due to acquired neuromuscular disease. The potential efficacy of leuprolide in such neuromuscular disorders provides a rationale for diagnostic motility studies in patients with "functional" gastrointestinal disorders. Topics: Adolescent; Chronic Disease; Cytomegalovirus Infections; Female; Gastric Emptying; Heart-Lung Transplantation; Humans; Immunosuppression Therapy; Intestinal Pseudo-Obstruction; Intestine, Small; Leuprolide; Postoperative Complications; Recurrence; Viremia | 1992 |
Debilitating "functional" bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog.
In this informal initial study, four female patients with intractable chronic abdominal pain, daily nausea, intermittent vomiting, and altered stool habits due to "functional" disease were investigated. A gonadotropin-releasing hormone (GnRH) analog agonist, leuprolide acetate (Lupron) [D-leu6, Desgly-NH2(10), Proethylamide9], was administered once daily (0.5 mg subcutaneously) for three months. At the end of the three-month period, three subjects were symptom-free and the fourth experienced only mild and intermittent pain. The leuprolide regimen was continued for an additional three months, and estrogen (0.625 mg orally) and calcium (1000 mg orally) were given daily to prevent osteoporosis. The patients remained symptom-free. A challenge with progesterone then induced recurrence of mild symptoms in each subject. Withdrawing leuprolide induced the baseline symptoms in all patients within three to five days. This regimen has now been continued for up to 15 months, and all four patients have remained generally symptom-free. Progesterone has also been given every three months to induce menses. A fifth patient, with Roux-en-Y syndrome, has also been treated with leuprolide. She is symptom-free after six months and has gained weight. In this initial observation period in patients with severe functional (neuromuscular) bowel disease, the GnRH analog agonist leuprolide controlled pain, nausea, and vomiting.(ABSTRACT TRUNCATED AT 250 WORDS) Topics: Adult; Anastomosis, Roux-en-Y; Chronic Disease; Colonic Diseases, Functional; Drug Evaluation; Female; Gonadotropin-Releasing Hormone; Hormones; Humans; Leuprolide; Middle Aged; Postoperative Complications; Syndrome; Time Factors | 1989 |